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Background: Recruitment is one of the most serious challenges in performing randomized controlled trials. Often
clinical trials with participants diagnosed with schizophrenia are terminated prematurely because of recruitment
challenges resulting in a considerable waste of resources in the form of time, funding, and the participants’ efforts.
Dropout rates in schizophrenia trials are also high.
Recruitment challenges are often due to patients not wanting to participate in research but can also be due to
clinicians’ concerns regarding individuals diagnosed with schizophrenia as participants in research. This paper
reports how overcoming recruitment challenges not related to patients revealed high readiness to take part and
low dropout rates in a one year long randomized controlled trial testing Guided Self-Determination (GSD) among
outpatients with schizophrenia receiving treatment in Assertive Outreach Teams in the northern part of Denmark.
Methods: GSD is a shared decision-making and mutual problem-solving method using reflection sheets, which was
developed in diabetes care and adjusted for this study and utilized by patients with schizophrenia. Descriptive data
on strategies to overcome recruitment challenges were derived from notes and observations made during the
randomized controlled trial testing of GSD in six outpatient teams.
Results: Three types of recruitment challenges not related to patients were identified and met during the trial:
1) organizational challenges, 2) challenges with finding eligible participants and 3) challenges with having
professionals invite patients to participate. These challenges were overcome through: 1) extension of time, 2)
expansion of the clinical recruitment area and 3) encouragement of professionals to invite patients to the study.
Through overcoming these challenges, we identified a remarkably high patient-readiness to take part (101 of 120
asked accepted) and a low dropout rate (8%).
Conclusion: Distinction between recruitment challenges was important in discovering the readiness among
patients with schizophrenia to take part in and complete a trial with the GSD-intervention.
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Randomized controlled trials (RCTs) are widely accepted
as the most powerful design for evaluating the efficacy
and effectiveness of health care interventions. However,
challenges with recruitment in RCTs are known to be
common and complex in health care, and frequently
more difficult than anticipated [1-4]. In a review from
2002, Gilbody et al. reported that in the past 50 years
less than 5% of schizophrenia trials had reached sufficient
power [5]. Further, it is a common understanding that
especially people with schizophrenia are difficult to recruit
into trials [5-7]. Additionally, dropout rates in drug trials
with people with schizophrenia were reported to be 65.9%
with the implication that dropout rates increase by length
of trial duration [8]. Also withdrawal from the treatment
without withdrawal from the trial is a common challenge.
In a review of 74 trials testing psychosocial treatment
among individuals diagnosed with schizophrenia, with-
drawal either prior to or during treatment was estimated
to be approximately 13% [9]. Delays in trials, withdrawal
from treatment in trials, high dropout and underpowered
trials have consequences with increases in cost and short-
comings in the scientific value of the intervention being
tested [10].
As a variety of challenges to recruitment and completion
of trials can be at play, distinctions between these chal-
lenges and barriers have been attempted and investigated
separately. Clinicians’ attitudes about recruiting participants
with severe mental illness for trials have been investigated
in qualitative studies [2,11]. Among other things, clinicians
were less likely to refer patients diagnosed with schizophre-
nia if they lacked knowledge of research methods and trials,
had concerns of increased workload or gave research a low
priority. Some clinicians were also likely to decide their
own inclusion criteria and make independent decisions
on behalf of their patients. These attitudes of recruiting
clinicians might be related to the fact that research partici-
pation of patients diagnosed with schizophrenia is an issue
of concern stated both by clinicians and researchers [12].
Concerns are leveled at patients’ decisional capacity [13],
understanding of ethical considerations [14], and na-
ture of voluntarism and motivations for participating
in research [15].
Among individuals with schizophrenia, recruitment
challenges and barriers as well as the above reasons for
participating in research have been explored. Challenges
and barriers regarding participation in research have been
connected with timing of approach, practical barriers,
conceptualization of mental health problems, concerns of
potential harm, and negative influence of other patients
[16,17]. Regarding reasons for participating in research
Chong et al. [15] found two main reasons for volunteering;
1) the possibility that I might get well, 2) I’m helping other
patients like myself, and a similar study Roberts et al. [18]found three main reasons; 1) helping other people, 2)
helping science, 3) gaining a sense of hope.
In order to further investigate the perspective of the
potential participant, patients with severe mental illnesses
admitted to a psychiatric hospital were interviewed about
their potential interest and readiness to participate in
research. Patients diagnosed with schizophrenia were
generally more reluctant to participate in trials, less
convinced that they would benefit from a new treatment
and indicated less often “to help science and other patients”
as their reason to participate compared to patients with
other mental disorders [19].
Within trial research it seems that the biggest challenge
is recruitment of potential participants.
Researchers must expect challenges regarding recruitment
due to patients not wanting to participate or clinicians’
concerns regarding individuals diagnosed with schizophre-
nia as participants in research. Also factors such as low
readiness to participate, withdrawal from treatment and
high dropout must be anticipated.
As recommended by Halpern et al. [10], we attempted
to identify potential recruitment challenges in our trial
beforehand and designed the trial according to those
considerations. Despite these considerations we neverthe-
less experienced challenges with recruitment.
This paper reports how recruitment challenges not
related to patient issues were overcome and revealed the
true readiness to take part in and complete a complex
clinical trial testing Guided Self-Determination (GSD)




The trial was approved by the Danish Data Protection
Agency and The Danish National Committee on Biomed-
ical Research Ethics under number VN-20070070. The trial
was also registered at ClinicalTrials.gov with identifier:
NCT01282307.
Design
The study design was descriptive, and based on data,
notes, and observations from a randomized controlled
trial testing a novel intervention in six outpatient teams.
During the recruitment period all eligible participants
were registered in a logbook containing information about:
participation in information meetings, reasons for declining
or participating in the trial, and comments regarding the
trial from either the eligible participant or his/her mental
health care professional (MHCP).
The observations and notes from the recruitment period
and the data collection were used to describe and distin-
guish the recruitment challenges not related to patients
from those connected with patients’ readiness to take part
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overcome them were described. In addition, data from the
trial were registered to report and calculate proportions of
withdrawal from treatment and dropout from the trial.
Withdrawal from treatment occurs when participants
withdraw from the intervention being tested in the trial ei-
ther prior to or during the treatment period but continue
in the data collection in the trial. Dropout is defined as
the participants who left the trial before the trial end [8,9].
The RCT
A total of 101 outpatients from three Assertive Outreach
Teams (AOT) and three District Teams (DT) in the
northern part of Denmark participated in the study.
Fifty-one were randomly assigned to the intervention
group which received an immediate individual training
program consisting of approximately ten sessions with
the Guided Self-Determination (GSD) method [20-24].
Fifty patients were randomly assigned to a waiting list
for a 12-month delayed individual training program
with GSD (control group). Both groups also continued
treatment as usual during the entire trial. Participants
completed four self-rating questionnaires, a demographic
data sheet (containing data about medication, alcohol use,
substance use and course of illness), an interview concern-
ing psychopathology and an assessment of social function-
ing at baseline and after 3, 6, and 12 months conducted in
their own home or in a team office according to the
participants’ preferences. Thirty-six MHCPs, primarily
registered nurses specially trained within psychiatry, pro-
vided the intervention and the principal investigator (PI)
(first author) conducted the data collection.
Setting
The study took place in Region North (0.6 million inhabi-
tants), the smallest of Denmark’s five Regions. Psychiatric
Health Care Services covers both inpatient (269 beds) and
outpatient care (approximately 4700 patients yearly) and
is publicly funded.
Study population
To be eligible for the trial, participants had to receive
treatment in an AOT or meet the requirements to receive
treatment in an AOT. Requirements for patients in AOTs
were: having frequent and/or long admissions poor or no
improvement in psychopathology and illness management,
frequent discontinuation of treatment, or relapse. Further
inclusion criteria for the trial were: meeting the criteria for
schizophrenia ICD-10 F.20.0-9 or schizoaffective disorder
F.25.0-9 according to participants’ hospital records,
age 18 – 70 years, ability to understand, speak and write
Danish, and signed informed written consent. The AOT
and DT treatment offered the following treatment modal-
ities: psychopharmacology, cognitive behavioral therapy,cognitive milieu therapy, psycho-education, and social
skills training, which was considered treatment as usual
(TAU) during the trial. Exclusion criteria were: previous
participation with the method GSD, having a mental
handicap or diagnosis of dementia or an organic brain
disease according to the hospital record, in need of an
interpreter to understand, speak and write Danish, and
withdrawal of informed consent. Statistical power calcula-
tion was performed which demonstrated that 50 partici-
pants in each group were needed.
Study information site visits
Before recruitment of participants, all teams were visited
by the PI and informed about the clinical trial and provided
with education about how to conduct the intervention
using the GSD method. Written information about the
recruitment process, the clinical trial and the GSD method
was given to each MHCP. Approximately 16 hours (over
2-3 days) of information and education were provided.
During the recruitment period the PI visited, mailed and/
or telephoned the teams and team members at least twice
a month to discuss eligible participants and to encourage
the MHCPs to participate in the trial, and was also
available for questions and supervision during the entire
trial, both in relation to the trial procedures and the
intervention.
Information and education were given to all MHCPs
(n = 43) in the six teams, as it was determined by the
hospital management as mandatory to participate in the
trial.
Recruitment
The MHCPs completed the recruitment strategy as part
of their clinical work. First, the MHCPs distributed a
patient information sheet for all eligible participants and
invited them to an individual appointment with the PI to
further discuss the trial. When the eligible participants
agreed to meet with the PI, the MHCP contacted the PI
and made arrangements for a meeting. According to the
person’s preferences the meetings took place either in the
person’s own home or in a team office. At the information
meeting the eligible participants often brought community
support workers, spouses or their MHCP. During the
meeting, detailed written information about the trial
was provided, oral information was given, and the eligible
participants were encouraged to ask questions. They were
then given time to make the decision about participation.
Some made their decision immediately and some made
it after a few days. For those who signed the informed
consent, an appointment for a baseline interview was
made.
Recruitment was an ongoing process, which started
with the implementation of the first AOT in February 2008
through July 2011.
Jørgensen et al. BMC Psychiatry 2014, 14:28 Page 4 of 10
http://www.biomedcentral.com/1471-244X/14/28The guided self-determination method
GSD is a shared decision making and problem-solving
method focusing on facilitating empowerment [25] devel-
oped from qualitative research using Grounded Theory
[20,22,23] originally developed for Type 1 Diabetes. The
method has been modified for other diagnoses, including
schizophrenia [26].
The purpose of the method is to guide the individual
through a process of exploring difficulties in living with
an illness systematically and creatively by means of words
and drawings and then to focus on which difficulties to
change in order to develop internally motivated self-
management of the illness [24]. GSD uses 21 reflection
sheets designed to guide the participant and MHCP
through a process of autonomy-supportive problem solv-
ing. The reflection sheets are completed by the participant
before, and between conversations with their MHCP, with
each entitled to have their own opinions and perceptions
about the content. More details about the GSD method
and a case study where an individual diagnosed with
schizophrenia used GSD are elaborated on elsewhere [26].
The GSD training in the trial was conducted with the
participants individually with an instructive and flexible
program consisting of 10 sessions, each lasting 30-60 mi-
nutes. The intervention period was decided to be six
months with a follow-up period of six months. No par-
ticipants were excluded from the trial if they spent more
than six months with the intervention.
Results
In the trial, barriers not related to patients were encoun-
tered. Three types of recruitment challenges not related
to patients were identified: 1) organizational challenges,
2) challenges with finding eligible participants, and
3) challenges with having professionals invite patients.
These challenges were overcome through: 1) extension of
time, 2) expansion of the clinical recruitment area, and
3) encouragement of professionals to invite patients to the
trial. Identifying and overcoming challenges not related to
patients disclosed remarkably high patient-readiness to
take part in the trial and a remarkably a low dropout rate
(Figure 1: Overcoming recruitment challenges not related
to patients revealed a high patient readiness).
Challenges to recruitment not related to patients and
strategies to overcome them
Organizational challenges
Prior to the trial, the hospital management had decided
that three future AOTs would be used for the study;
therefore, the original trial protocol was designed in
accordance with the plan of establishing the three AOTs
and was considered to be feasible. Only a few months after
the trial started, however, this plan was changed politically
in order to reduce cost and because of difficulties inemploying psychiatrists to work in the AOTs. This
accounted for a considerable delay in the implementation
plan. According to the original implementation plan,
the three AOTs were supposed to be started in January
2008 to August 2008, but the last AOT was not imple-
mented until August 2009, which ended up being a
12 month-delay.
To overcome this challenge and to avoid early ter-
mination of the trial and an underpowered trial, a time
extension was judged necessary. The recruitment period
was from January 2008 until November 2009, but was
extended until July 2011 – an extension of 20 months
(Figure 2: Time line for recruitment in project GSD).
Challenges finding eligible participants
In addition to the delay in the implementation plan, the
number of expected eligible participants for the trial de-
creased. The AOTs were expected to treat approximately
300 patients, and it was also expected that 90 to 95% of the
patients (n = 280) in the AOTs would have a diagnosis of
schizophrenia. In total, 24 MHCPs were expected to be
employed, but due to changes in the implementation plan
the actual number was 18 MHCPs, which reduced the total
patients by a third. Some MHCPs resigned, and new ones
were employed, but the total number was 18 MHCPs dur-
ing the entire trial period. Without any proper explanation,
the number of patients with a diagnosis of schizophrenia
was smaller than expected. It appeared that only between
60 and 65% of the patients treated in the AOTs had schizo-
phrenia, 30 to 35% less than expected. Looking at the num-
bers of patients in the three AOTs when the recruitment
period ended, we found that 201 patients were treated in
the AOTs and only 128 met the inclusion criteria for the
trial. Five MHCPs from the AOTs did not participate in the
trial; therefore 34 eligible participants were not approached
or asked to participate in the trial. In total 94 eligible partic-
ipants were present in the three AOTs compared to the ex-
pected 280 eligible participants in the implementation plan,
a reduction of 66% (Figure 3: Flowchart for recruitment).
The challenge of finding enough eligible participants
was overcome by an expansion of the clinical area. Three
District Teams (DT) were included in the trial, and eligible
participants from the DTs had to meet the requirements to
receive treatment in an AOT besides the inclusion criteria
for the trial. Seventy-six eligible participants were identified
in the three DTs.
The MHCPs from the DTs had to undergo the same
education as the MHCPs from the AOTs which also
affected the time extension.
Challenges to having mental health care professionals
invite patients
When the MHCPs were informed and provided education
about the trial, the recruitment process and the GSD
Figure 1 Overcoming recruitment challenges not related to patients revealed a high patient-readiness.
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mainly consisted of how to manage the increase of work-
load and questions whether the eligible participants either
were too severely ill to participate in research or to make
the decision to participate in research.
In total, 20 MHCPs in the AOTs and 23 MHCPs in the






















































Figure 2 Time line for recruitment in project GSD. AOT1: Assertive Out
Outreach Team3. DT1: District Team1, DT2: District Team2, DT3: District Teatrial. Altogether 36 of the 43 MHCPs took part in the trial
as five MHCPs from the AOTs and two MHCPs from the
DTs (in all 16%) did not participate.
Most of the non-participating MHCPs did not openly
express their reluctance in the beginning, but communi-
cated a kind of avoidance or “silent reluctance” by not an-
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Figure 3 Flowchart for recruitment.
Jørgensen et al. BMC Psychiatry 2014, 14:28 Page 6 of 10
http://www.biomedcentral.com/1471-244X/14/28meetings with the PI, or avoiding providing the information
sheet to eligible participants. Two MHCPs actively denied
informing eligible participants about the trial, as they
believed that the trial would harm the patients or that
the patients were too ill to participate. Among the partici-
pating MHCPs, some expressed concerns during the trial
regarding patients’ vulnerability and severe psychopath-
ology and asked if it was necessary to provide the informa-
tion sheet to all eligible participants. All eligible patients
(N = 170) should have received the information sheet and
been invited to an information meeting. It is not possible
to decide if it actually occurred. Another barrier besides
these concerns was the fact that the MHCPs’ main focus
was the establishment of the AOTs and not research, even
though the hospital was established as a university hospital.
The challenge with having professionals invite patients
to the trial was overcome by attempting to encourage theMHCPs to prioritize the trial. The frequency of contact
between PI and the MHCPs was increased from once a
month to at least twice a month. The MHCPs were either
visited, received mailing and/or were telephoned by the PI
to discuss eligible participants and encourage the MHCPs
to participate in the trial. The PI was available for ques-
tions and supervision during the entire trial, both in
relation to the trial procedures and the intervention.
Further it was decided to accept non-participation from the
16% of the MHCPs that either denied or avoided to recruit
eligible participants.
Patients’ readiness to take part in GSD and the trial
When distinguishing recruitment challenges not related to
patients from those related to patients’ readiness to take
part in the trial, it became clear that the latter challenges
were only a few.
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were 170 eligible participants; 70% (n = 120) participated
in the information meeting and 84% (n = 101) signed in-
formed consent. In total 59% of the eligible participants
signed the informed consent. In general, the eligible par-
ticipants participating in the information meeting were
open-minded towards research and participation in the
trial. Many spontaneously expressed their motivation to
participate in the trial and “helping myself and others”
was the most frequently mentioned reason. The two main
reasons for eligible participants to decline participation
appeared to be severe psychopathology, and delusional
thinking related to the trial, for example that personal data
would be shared with the FBI or the Government. Reasons
for declining to participate in the information meeting
were severe psychopathology, timing of approach and
practical barriers. However, those reasons were expressed
by the MHCPs and not by the eligible participants, as the
PI was not in contact with the eligible participants until
the information meeting.
No new strategies were employed to meet challenges
with eligible participants, as the eligible participants dem-
onstrated high readiness to take part in the trial.
Further withdrawal from treatment and dropout from
the trial were calculated. In total 7% of the participants
withdrew from the treatment in the trial; 3% never started
working with the GSD method (2/3 of these participants
stayed in the trial with data collected at all times), and dur-
ing the trial 4% stopped treatment before it was completed.
The reasons reported for withdrawal from treatment were;
timing of approach (n = 3), death (n = 1), moving out of the
country (n = 1), pregnancy (n = 1) and loss of a family
member (n = 1).
The total dropout rate was 8% of the participants (3%
in the control group and 5% in the intervention group).
As some participants both withdrew from treatment and
dropped out of the trial, the reasons reported for dropout
were similar with the reasons reported for withdrawal: tim-
ing of approach, moving out of the country, loss of a family
member, severe psychopathology and a brain injury.
Discussion
Addressing challenges and barriers to recruitment en-
countered in this trial appeared to be fruitful and led
to the conclusion that barriers, not related to patients,
were at play in contrast to what is often reported by a great
majority of the research literature. Through overcoming
these challenges, we actually identified remarkably high
patient readiness to take part and a low dropout rate.
Three types of recruitment challenges not related to
patients were identified and met during the trial:
1) organizational challenges, 2) challenges with finding
eligible participants and 3) challenges with having pro-
fessionals invite patients. The challenges were overcomethrough: 1) extension of time, 2) expansion of the clin-
ical recruitment area and 3) encouragement of profes-
sionals to invite patients to the study.
Challenges to recruitment not related to patients and
strategies to overcome them
To our knowledge organizational challenges have not
prior been described as recruitment barriers. Our trial was
planned according to the original implementation plan for
the AOTs. As a consequence of the unanticipated changed
plan, we first experienced a delay in the implementation,
which was met with a time extension, a commonly used
strategy in trials [27]. As mentioned by Halpern et al. [10],
delays lead to increased costs, which also was the case in
our trial, meaning that we had to apply for more external
funding and ask the hospital management to ensure finan-
cial support. Extension of time in itself is rarely adequate
to achieve the original recruitment target [27].
The next challenge that occurred due to the changed
implementation plan was finding eligible participants, as
the total number of eligible participants was reduced
to 66% in the AOTs. Consequently we had to apply an
additional strategy: expanding the clinical area. We
knew that some of the patients in the DTs were eligible
to receive treatment in an AOT, since an assessment of all
outpatients conducted ahead of the implementation had
revealed existence of patients fitting the criteria, although
the AOTs had insufficient capacity for including them.
Organizational changes can happen during a trial and
affect the design, so the consequences can be early termin-
ation or adaptation of the trial design. We adapted the
trial design without crucial alterations, as the randomized
controlled trial design is a very rigorous design.
The third barrier not related to patients was challenges
having professionals invite eligible participants to the trial.
The MHCPs were the primary access to the eligible
participants and the ones conducting the intervention.
Primary MHCPs can play an important role in facilitating
the recruitment process, as most patients trust them [19].
Some of the MHCPs were not willing to or hesitant to
inform or recruit eligible participants. They expressed
concern about patients’ capability to participate in re-
search or make decisions about participation in research,
and believed that the trial might complicate patients’
psychopathology. The MHCPs’ lack of knowledge of re-
search and research methods is known to be a barrier
[2,11,28]. The MHCPs in the trial were mostly registered
nurses (n = 33) without much knowledge of or prior ex-
perience with research. Nursing Science in Denmark has
a very short tradition for conducting research in clinical
practice. To overcome the lack of knowledge, we before-
hand provided the MHCPs with information about the
trial, the recruitment process, and training in utilizing the
GSD method. During the trial the MHCPs were provided
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once a month, but increased to be twice a month.
Still some of the MHCPs seemed to assess eligibility
according to their own inclusion criteria, assumedly be-
cause of a personal idiosyncratic belief that patients need
protection against research, which has been described by
Howard et al. [2]. MHCPs are generally found lacking
confidence in patients’ ability to make decisions [29],
though patients are both willing and able to be involved
in decisions [30]. Especially decisional capacity regarding
participation in research is of great concern to MHCPs,
but the presence of a diagnosis of schizophrenia is not
an indication that an individual should be unable to give
competent consent to research participation [13]. Of note,
the ability of individuals with schizophrenia to make com-
petent decisions relates more to their overall cognitive func-
tioning than to the severity of specific positive or negative
symptoms [31-33]. In addition, research points towards the
fact that individuals with schizophrenia, who reported more
severe psychiatric symptoms, expressed less willingness to
participate in research [14]. The latter is in accordance with
the reasons given for refusal to participate by some of the
eligible participants in our trial and indicates that individ-
uals with severe psychopathology are able to take care of
themselves, when asked to participate in research.
We did not ask the MHCPs structured questions about
their attitudes of recruiting participants to the trial. How-
ever, most of the MHCPs expressed their opinions through
spontaneous conversation, comments or even avoidance,
and it did not differ from what has been described in prior
studies [2,11].
Patients’ readiness to take part in GSD and the trial
After the recruitment challenges not related to patients
were overcome, we identified remarkably high patient
readiness to participate in the trial, a low withdrawal
from treatment and a low dropout from the trial.
In general, the eligible participants were open-minded
and positive towards the trial when they participated in
the information meeting. We cannot conclude that all
eligible participants were positive towards the trial, as
the PI only spoke to the eligible participants who partic-
ipated in the information meeting. In total 59% of the
total eligible participants signed informed consent, but
84% of the eligible participants participating in the infor-
mation meeting signed informed consent. Those numbers
are remarkably high comparing to the study of Zullino
et al. [19], who reported an overall hypothetical accept-
ance rate above 70% among in-patients with severe mental
illnesses, with a general lower acceptance rate among indi-
viduals with schizophrenia, expecting this number to be
much lower in a real recruitment situation.
The reasons expressed by the eligible participants
that declined to participate in the trial were severepsychopathology or delusions. Those reasons are in agree-
ment with those found in the literature [16,17,34]. We did
not ask the participants directly for their motivation to
participate, but those who expressed it spontaneously
often stressed “helping other people or helping myself” as
an important factor to participate in the trial, which were
in accordance with the findings from Chong et al. [15]
and Roberts et al. [18].
Both the rate of withdrawal from treatment (7%) and
total dropout from our trial (8%) were lower than reported
in reviews [5,9]. Villeneuve et al. [9] reported a withdrawal
of 13% from their review. Our trial lasted for 52 weeks
and the withdrawal number from the review was reported
for trials lasting approximately 26 weeks on average. Add-
itionally, Villeneuve et al. [9] reported factors that might
have a negative effect on the withdrawal rate such as,
increased age, longer illness duration, longer treatment
duration and being male. Our participants were out-
patients with a mean age of 37.5, illness duration above
10 years, treatment duration with the GSD method was
26 weeks and 47% of the participants were men. It seems
that the factors mentioned in the review by Villeneuve
et al. [9] did not apply fully to our study indicating that
other factors might be at play regarding impact on with-
drawal rates. Additionally, they also reported factors that
might have a positive effect on the withdrawal rate as,
study quality and hospitalized subjects [9]. The partici-
pants in our trial might have found the GSD intervention
relevant and useful, and the study quality high.
Commonly, dropout rates in trials are reported to be
high. According to Gilbody et al. [5] in trials of new anti-
psychotics, up to 60% dropped out, and in a meta-analysis
[8] of trials assessing antipsychotic medication in the
treatment of schizophrenia, dropout rates ranged from
0-65.9%, showing that the duration of the trial increased
dropout rates remarkably.
Gilbody et al. [5] suggested that minimal effort on the
part of participants and minimal deviation from routine
care, and understanding what the patients perceive as a
relevant outcome, might have an impact on the motivation
of patients with schizophrenia to participate and stay in
trials. Taking Gilbody’s suggestions into account, this trial
was an effectiveness trial within a real world setting. Par-
ticipants were seen in their own homes during the inter-
vention, but also during the data collection. As mentioned
prior, the participants might have found the GSD inter-
vention relevant and useful, but also the outcome mea-
sures of the trial might have been relevant and motivated
the participants to participate and stay in the trial.
Conclusion
Three types of recruitment challenges not related to
patients were identified and overcome during the trial. By
overcoming these challenges we found remarkably high
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The distinction between the recruitment challenges was
important in discovering the readiness among patients
with schizophrenia to take part in and complete a trial
with the GSD intervention.
The limitations of this study are that the challenges
and the strategies are descriptive, based on data, notes
and observations from the trial. We cannot directly
confirm that the strategies caused the completion of
the trial; we can only assume that the strategies had an
impact. Moreover we have not further investigated whether
or how the patients’ readiness to take part and complete
the trial was connected with a perception of high quality
of the GSD intervention as expressed by one patient in a
case study. Especially the patient-provider collaboration
and the content of the reflection sheets were emphasized
as very important contribution to feeling believed and in
charge [26].
The strength of the study is that we openly report
recruitment challenges and strategies to provide meth-
odological transparency of this trial to other researchers.
Further, we address organizational challenges and barriers,
which have been given limited attention until now, but
seem to be important factors that researchers need to
consider when planning or revising future trials.
Most importantly, we have drawn attention towards
the value of thoroughly distinguishing between recruitment
challenges. If we do not question the assumption that
recruitment challenges are mostly related to the patients,
researchers might overlook the importance of and ability
to overcome other recruitment challenges. By overcoming
them we might identify which interventions patients with
schizophrenia prefer to take part in which can provide in-
formation for further investigating what the patients find
beneficial to assist them in more effectively living with
their illness.
Abbreviations
AOT: Assertive outreach team; DT: District team; RCT: Randomized controlled
trial; GSD: Guided self-determination; MHCP: Mental health care professional;
PI: Principal investigator.
Competing interests
The authors declare that they have no competing interests.
The study was funded by Aalborg Psychiatric Hospital, The Novo Nordisk
Foundation, The Health Insurance Foundation, and TrygFonden, but they
had no influence on planning the study or preparing the manuscript.
Authors’ contributions
Authors RJ, PMJ and VZ designed the study and wrote the protocol. Author
RJ managed the literature searches and the data collection. Authors RJ and
VZ wrote the first draft of the manuscript. Authors PMJ, KB, PL and LH
commented on the first manuscript and contributed to the writing of the
subsequent manuscript versions. All authors contributed in the finalization of
the manuscript and have approved the final version.
Author details
1Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aalborg University
Hospital, Mølleparkvej 10, 9000 Aalborg, Denmark. 2Department M, Aarhus
University Hospital, Aarhus, Denmark. 3Roudebush Veteran Affairs MedicalCenter, Indianapolis IN, USA. 4Indiana University School of Medicine,
Indianapolis, USA. 5Lund University, Lund, Sweden. 6Steno Diabetes Center,
Gentofte, Denmark. 7NKLMS Oslo University Hospital, Oslo, Norway.
Received: 6 March 2013 Accepted: 29 January 2014
Published: 3 February 2014
References
1. de Salis I, Tomlin Z, Toerien M, Donovan J: Using qualitative research
methods to improve recruitment to randomized controlled trials: the
Quartet study. J Health Serv Res Policy 2008, 13(Suppl 3):92–96.
2. Howard L, de Salis I, Tomlin Z, Thornicroft G, Donovan J: Why is
recruitment to trials difficult? An investigation into recruitment
difficulties in an RCT of supported employment in patients with severe
mental illness. Contemp Clin Trials 2009, 30(1):40–46.
3. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R: Barriers to
participation in randomised controlled trials: a systematic review. J Clin
Epidemiol 1999, 52(12):1143–1156.
4. Toerien M, Brookes ST, Metcalfe C, de Salis I, Tomlin Z, Peters TJ, Sterne J,
Donovan JL: A review of reporting of participant recruitment and
retention in RCTs in six major journals. Trials 2009, 10:10–52.
5. Gilbody S, Wahlbeck K, Adams C, et al: Randomized controlled trials in
schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand
2002, 105:243–251.
6. Ghio L, Natta W, Barbato A, et al: Schizophrenia trial participation:
perceived inclusion barriers and beliefs about antipsychotics.
Pharmacopsychiatry 2011, 44:123–128.
7. Lester H, Wilson S: Practical problems in recruiting patients with
schizophrenia into randomized controlled trials. Br Med J 1993, 318:1075.
8. Martin JLR, Pérez V, Sacristán M, et al: Meta-analysis of drop-out rates in
randomized clinical trials, comparing typical and atypical antipsychotics
in the treatment of schizophrenia. Eur Psychiatry 2006, 21:11–20.
9. Villeneuve K, Potvin S, Lesage A, et al: Meta-analysis of rates of drop-out
from psychosocial treatment among persons with schizophrenia
spectrum disorder. Schizophr Res 2010, 121:266–270.
10. Halpern SD, Karlawish JH, Berlin JA: The continuing unethical conduct of
underpowered clinical trials. JAMA 2002, 288(3):358–362. 17.
11. Patterson S, Kramo K, Soteriou T, Crawford MJ: The great divide: a
qualitative investigation of factors influencing researcheraccess to
potential randomised controlled trial participants in mental health
settings. J Ment Health 2010, 19(6):532–541.
12. Applebaum PS: Decisional capacity of patients with schizophrenia to
consent to research: taking stock. Schizophr Bull 2006, 32(1):22–25.
13. Carpenter WT, Gold JM, Lahti AC, et al: Decisional capacity for informed
consent in schizophrenia research. Arch Gen Psychiat 2000, 57:533–538.
14. Roberts LW, Warner TD, Hammond KG, et al: Views of people with
schizophrenia regarding aspects of research: study size and funding
sources. Schizophr Bull 2006, 32(1):107–115.
15. Chong S, Ong YY, Subramaniam M, et al: An assessment of the
understanding and motivations of patients with schizophrenia anout
participating in a clinical trial. Contemp Clin Trials 2009, 30:446–450.
16. Woodall A, Morgan C, Sloan C, Howard L: Barriers to participation in
mental health research: are there specific gender, ethnicity and age
related barriers? BMC Psychiatry 2010, 2:10–103.
17. Woodall A, Howard L, Morgan C: Barriers to participation in mental health
research: findings from the Genetics and Psychosis (GAP) Study. Int Rev
Psychiatry 2011, 23(1):31–40.
18. Roberts LW, Warner TD, Brody JL: Perspectives of patients with
schizophrenia and psychiatrists regarding ethically important aspects of
research participation. Am J Psychiatry 2000, 157:67–74.
19. Zullino D, Conus P, Borgeat F, et al: Readiness to participate in psychiatric
research. Can J Psychiatry 2003, 48(7):480–484.
20. Zoffmann V, Kirkevold M: Life versus disease in difficult diabetes care:
conflicting perspectives disem- power patients and professionals in
problem solving. Qual Health Res 2005, 15(6):750–765.
21. Zoffmann V, Lauritzen T: Guided self-determination improves life skills
with Type 1 diabetes and A1C in randomized controlled trial. Patient
Educ Couns 2006, 64(1–3):78–86.
22. Zoffmann V, Kirkevold M: Relationships and their potential for change
developed in difficult type 1 diabetes. Qual Health Res 2007,
17(5):625–638.
Jørgensen et al. BMC Psychiatry 2014, 14:28 Page 10 of 10
http://www.biomedcentral.com/1471-244X/14/2823. Zoffmann V, Harder I, Kirkevold M: A person-centered communication and
reflection model: sharing decision-making in chronic care. Qual Health
Res 2008, 18(5):670–685.
24. Zoffmann V, Kirkevold M: Realizing empowerment in difficult diabetes
care: a guided self-determination intervention. Qual Health Res 2011,
22(1):103–118.
25. Anderson B, Funnell M: The Art of Empowerment. Alexandria, VA: American
Diabetes Association; 2000.
26. Jørgensen R, Hansson L, Zoffmann V: Changes in persistent delusions in
schizophrenia using guided self-determination: a single case study. Issues
Ment Health Nurs 2012, 33:293–300.
27. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA,
Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C: What influences
recruitment to randomised controlled trials? A review of trials funded by
two UK funding agencies. Trials 2006, 7:7–9.
28. Mason VL, Shaw A, Wiles NJ, Mulligan J, Peters TJ, Sharp D, Lewis G: GPs’
experiences of primary care mental health research: a qualitative study
of the barriers to recruitment. Fam Pract 2007, 24(5):518–525.
29. Hugo M: Mental health professionals’ attitudes towards people who
have experienced a mental health disorder. J Psychiatr Ment Hlt 2001,
8:419–425.
30. Valimaki M, Leino-Kilpi H, Helenius H: Self-determination in clinical practice:
the psychiatric patient’s point of view. Nurs Ethics 1996, 3:329–344.
31. Kovnick JA, Appelbaum PS, Hoge SK, Leadbetter RA: Competence to consent
to research among long-stay inpatients with chronic schizophrenia.
Psychiatr Serv 2003, 54:1247–1252.
32. Moser DJ, Schultz SK, Arndt S, et al: Capacity to provide informed consent
for participation in schizophrenia and HIV research. Am J Psychiat 2002,
159:1201–1207.
33. Palmer BW, Dunn LB, Appelbaum PS, et al: Assessment of capacity to
consent to research among older persons with schizophrenia, Alzheimer
disease or diabetes mellitus: comparisons of a 3-items questionnaire
with a comprehensive standardized capacity instrument. Arch Gen
Psychiatr 2005, 62:726–733.
34. Barnes M, Wiles N, Morrison J, Kessler D, Williams C, Kuyken W, Lewis G,
Turner K: Exploring patients’ reasons for declining contact in a cognitive
behavioural therapy randomised controlled trial in primary care. Br J Gen
Pract 2012, 62(598):371–377.
doi:10.1186/1471-244X-14-28
Cite this article as: Jørgensen et al.: Overcoming recruitment barriers
revealed high readiness to participate and low dropout rate
among people with schizophrenia in a randomized controlled trial testing
the effect of a Guided Self-Determination intervention. BMC Psychiatry
2014 14:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
